about
Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317].Anti-inflammatory therapy in chronic disease: challenges and opportunitiesInvasive aspergillosis in the intensive care unitThe PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibitionLabel-free cytokine micro- and nano-biosensing towards personalized medicine of systemic inflammatory disordersEarly interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major traumaChronic morphine administration delays wound healing by inhibiting immune cell recruitment to the wound site.Glycyrrhizin Protects Rats from Sepsis by Blocking HMGB1 SignalingDivergence of protection induced by bacterial products and sepsis-induced immune suppression.Risk factors for death after sepsis in patients immunosuppressed before the onset of sepsis.Improved resistance to bacterial superinfection in mice by treatment with macrophage migration inhibitory factor.Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells.Regulation of Toll-like receptor (TLR)2 and TLR4 on CD14dimCD16+ monocytes in response to sepsis-related antigens.Experimentally approaching the ICU: monitoring outcome-based responses in the two-hit mouse model of posttraumatic sepsis.Glutamine: essential for immune nutrition in the critically ill.Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shockInflammation and coagulation: implications for the septic patient.Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma.CCR4 Controls the Suppressive Effects of Regulatory T Cells on Early and Late Events during Severe Sepsis.The late phase of sepsis is characterized by an increased microbiological burden and death rateBeyond sepsis pathophysiology with cytokines: what is their value as biomarkers for disease severity?The mRNA expression patterns of tumor necrosis factor-alpha and TNFR-I in some vital organs after thermal injury.Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock.Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factorChloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury.Invasive aspergillosis among heart transplant recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction syndrome.Bench-to-bedside review: Developmental influences on the mechanisms, treatment and outcomes of cardiovascular dysfunction in neonatal versus adult sepsis.Advances in understanding sepsisA Biohybrid Device for the Systemic Control of Acute Inflammation.Inflammation and immunosuppression in severe acute pancreatitis.Invasive Primary Colonic Aspergillosis in the Immunocompetent Host without Classical Risk Factors.Interleukin-10 gene down-expression in circulating mononuclear cells during infusion of drotrecogin-α activated: a pilot studyThe clinical course of acute pancreatitis and the inflammatory mediators that drive it.Differential effects of glucocorticoids in the establishment and maintenance of endotoxin tolerance.Effect of neutrophil apoptosis on monocytic cytokine response to Porphyromonas gingivalis lipopolysaccharideCalcitonin gene related peptide and N-procalcitonin modulate CD11b upregulation in lipopolysaccharide activated monocytes and neutrophils.Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules.CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) /CD16(neg) monocytes: Expansion of CD14(hi) /CD16(pos) and contraction of CD14(lo) /CD16(pos) monocyteDevelopment and validation of immune dysfunction score to predict 28-day mortality of sepsis patients.Predictors of treatment failure and clinical stability in patients with community acquired pneumonia.
P2860
Q24813329-73EBB84B-6330-4B5D-83ED-69A9269E3D55Q26860162-D130692B-5985-41EE-B632-CC1D047384ABQ28306909-7041C3E9-048C-4C73-9453-D82516EB9751Q28572346-D004D30C-C26B-43DD-B7F9-98C8CDFF80A9Q30368512-EBBC1347-D7EF-4EA1-AEA2-0A78B4ABDAE1Q31052251-62CFC2B5-6C65-42CD-A941-E00514C4B0BCQ33597153-575FF093-CAFF-4068-BFB6-6CBA0B4530B0Q33624172-4219BA87-7465-456B-8703-A390239AD5FFQ33946614-3FD272DE-E497-477F-B631-E602606712D6Q34031614-3E33596F-FECE-4B37-93B2-5063D1EED6A5Q34033247-2C0DA968-81B7-4C34-93D6-76D25B459C38Q34189365-6EBA5631-0804-4185-85B6-73BFE4455198Q34559002-FE847A99-9D19-4517-825C-0F24B667F2F7Q34561423-287FE52B-7B96-49C1-BBBD-7A89B821174DQ34564510-9C14CC5F-8932-4212-A073-C627A7FC65E9Q34697264-1034C98E-ABFA-49CC-8081-1BB3F38782A8Q35127410-33DB26FB-D1BD-4FBB-AB45-4C0BB4B1B5BFQ35561379-8AD486C7-0621-4B79-A365-226B712504F0Q35703434-9B19AEA3-7232-4D78-978D-CAFB2DCD3D80Q36070469-1EB8C86B-3682-412D-9848-49C712DE45FEQ36165942-74B99AE9-2204-4829-AFA7-5262B18CE9C1Q36178447-130CA06C-16C2-4FDE-A04B-E2BCBDD887A4Q36489505-1C8003AD-715E-489F-A643-DC3D48A7F048Q36641962-056278FF-46A6-4839-9DFE-4D41B026B2EBQ36661052-1F37CC3A-FCC0-4EEA-B7A9-40241CA73594Q36939531-B9E7CF33-1F31-4C1A-A228-E1BC6F6D3391Q36954654-72294A5A-E526-4EB0-89D6-3D63E28D05E3Q37090618-12C7EA04-C217-4763-BA4D-5A0B42F6B6EBQ37280616-729AAAA2-8D31-430C-BC16-67F67462FD7FQ37765879-7CB7273A-3E50-4621-8E64-959B44600619Q38563506-F06AAF79-A9AC-4763-A7C3-A10253E9AA6CQ39197431-F52ADFCC-277D-4672-8089-FF39C796DE59Q39488367-9BDCE5A4-481B-4B3D-985C-25F4A116D94BQ39929445-4B6EDD1D-F720-44B0-BE38-FE96A00649DBQ41896374-1A3B568C-0BDB-4652-9CD1-103E8402886AQ44415054-A7EF549B-9CE6-4787-B578-87FD7F2E9D11Q44829699-62D69660-68EA-4C1E-B2A7-5C960AD8C8C3Q45278901-697139A5-6D00-41D2-AD6F-AD1BC088221FQ47108921-3A44B0A4-F253-4383-A23A-2EB297C10C37Q47160389-2DC611DC-F794-4FD0-8E41-0BB33412E9BE
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Immunomodulatory therapies in sepsis.
@ast
Immunomodulatory therapies in sepsis.
@en
type
label
Immunomodulatory therapies in sepsis.
@ast
Immunomodulatory therapies in sepsis.
@en
prefLabel
Immunomodulatory therapies in sepsis.
@ast
Immunomodulatory therapies in sepsis.
@en
P2093
P356
P1476
Immunomodulatory therapies in sepsis.
@en
P2093
P2888
P304
P356
10.1007/S001340051129
P478
26 Suppl 1
P577
2000-01-01T00:00:00Z